PhD, University of Helsinki
Emmy Verschuren is a Dutch cancer biologist interested in understanding how personal, research, as well as sociocultural environments can be optimised to promote health. Her team at the Institute for Molecular Medicine Finland (FIMM) studies a variety of diagnostic lung cancer models, aiming to ameliorate the prognosis of patients treated in the nearby hospital, and prevent disease recurrence.
Dr. Verschuren graduated from the University of Groningen with a Master’s in tumour immunology. She trained in notable labs at the ICRF/CRUK, UCSF, Stanford University and Genentech Inc., and, in a nutshell, researched how altered mechanisms and timing of the process by which cells divide (cell cycle) can affect cancer risk. In ’09, she was the first international FIMM-EMBL Group Leader recruit at FIMM, an institute with a mission to understand drivers of health and disease and deliver key findings to healthcare in Finland and beyond.
Prior to CANCERPREV, Dr. Verschuren acted as the academic coordinator of the IMI consortium PREDECT (’11-’16). In this EU project, universities, institutes and private companies collaborated to develop cancer models that represent the architecture and complexity of human cancers, to ameliorate anti-cancer drug development in industry. She has been a European Association for Cancer Research (EACR) Board Member since (’12-‘20), and helped develop their successful Goodbye Flat Biology Conference. Since autumn ‘18, she has been supporting the FIMM Director Mark Daly with the coordination of international initiatives and partnerships, and continues her role as a FIMM Group Leader.
Find out more about Dr Verschuren’s team and research focus here.